Infectious Disease

FDA approves Asahi Kasei’s Hovilpri for refractory HSV

The US Food and Drug Administration (FDA) has approved Asahi Kasei Therapeutics’ Hovilpri (pritelivir) 100mg tablets to treat refractory mucocutaneous herpes simplex virus (HSV) lesions in immunocompromised adults.

Gilead and PAHO agree to expedite lenacapavir access for HIV prevention

Gilead Sciences and the Pan American Health Organization (PAHO) have signed an agreement to expedite access to the company’s twice-yearly lenacapavir injection for human immunodeficiency virus (HIV) prevention as pre-exposure prophylaxis (PrEP) across Latin America and the Caribbean.

LSTM opens $23m robotic AI lab for infection research

The Liverpool School of Tropical Medicine (LSTM) in the UK has opened a £20m ($23.2m) robotic AI laboratory to test drugs and vaccines against infections and diseases.

Charles River and MVC to develop enterovirus vaccine

Charles River Laboratories International and Medigen Vaccine Biologics (MVC) have entered a collaboration to support the characterisation along with validation of the virus seed bank for the latter’s next-generation multivalent enterovirus vaccine.

JCVI issues recommendation on adolescent MenB vaccination in UK

The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended a routine programme with the 4CMenB vaccine for adolescents.

CHMP endorses Pfizer-BioNTech’s updated Covid-19 vaccine

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended marketing authorisation for Pfizer and BioNTech’s LP.8.1-adapted monovalent Covid-19 vaccine.

FDA approves Hikma’s Tyzavan for multiple infections

The US Food and Drug Administration (FDA) has granted approval for Hikma's Tyzavan (Vancomycin Injection, USP), a ready-to-infuse vancomycin formulation.

Evotec secures $2.5m grant for TB treatment development

German life science company Evotec has been awarded a $2.5m grant from The Gates Foundation (GF) to enhance the development of tuberculosis (TB) treatment regimens.

Valneva submits application seeking FDA approval for IXCHIQ for adolescent use

Valneva has submitted an application to the US Food and Drug Administration (FDA) seeking approval for a label extension of its chikungunya vaccine, IXCHIQ.